Despite its "high-risk" reputation, neuroscience attracted over $1.5B in venture funding last year while delivering breakthrough treatments for Alzheimer's, ALS, and pain disorders. Explore how industry leaders are navigating this complex landscape in this Trendline
|
Access now to discover how the field is progressing, including:
|
-
Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment
-
A new, non-opioid pain drug is here. Getting it to patients could be agony.
-
Psychiatry drugs finally have pharma’s attention. Can they keep it?
|
|
This Trendline is independently produced by our journalists. The support of our sponsors makes this journalism possible. Want to learn about sponsorship opportunities? Contact us directly at advertising@industrydive.com.
|
|
|
|
